The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute lymphoblastic leukaemia (ALL).Original Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.